<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571216</url>
  </required_header>
  <id_info>
    <org_study_id>V10.1</org_study_id>
    <nct_id>NCT04571216</nct_id>
  </id_info>
  <brief_title>Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy</brief_title>
  <acronym>CESTO2</acronym>
  <official_title>Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NFL Biosciences SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NFL Biosciences SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CESTO 2 is a 318 participants, 3-arm, multicentric, randomized, double-blind,&#xD;
      placebo-controlled Phase II clinical trial.&#xD;
&#xD;
      The main objectives are to select the most efficient dose and to assess long-term efficacy of&#xD;
      NFL-101 compared to placebo, for abrupt cessation and for reduction before cessation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term smoking cessation or reduction had been observed in thousands of patients when 1 or&#xD;
      2 subcutaneous injections of a desensitization treatment against tobacco allergy were taking&#xD;
      place concomitantly with Target Quit Date (TQD). NFL Biosciences SAS developed a tobacco&#xD;
      cessation drug candidate (NFL-101) consisting of a nicotine-free extract of tobacco proteins.&#xD;
      According to the observations made during CESTO, a Phase I study on 24 smokers, NFL-101&#xD;
      appears to work by reducing cigarette appetence immediately and over a week after each&#xD;
      injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participants achieving 4-week continuous abstinence</measure>
    <time_frame>4-week</time_frame>
    <description>4-weekcontinuous abstinence measured from D15 to D43</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of participants achieving 6-month continuous abstinence</measure>
    <time_frame>6-month</time_frame>
    <description>6-month continuous abstinence measured from D15 to M6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving 12-month continuous abstinence</measure>
    <time_frame>12-month</time_frame>
    <description>12-month continuous abstinence measured from D15 to M12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving 3-month continuous abstinence</measure>
    <time_frame>3-month</time_frame>
    <description>3-month continuous abstinence measured from D15 to M3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving 3-month continuous abstinence End of Treatment</measure>
    <time_frame>3-month</time_frame>
    <description>continuous abstinence measured during 3-month after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving 6-month continuous abstinence End of Treatment</measure>
    <time_frame>6-month</time_frame>
    <description>continuous abstinence measured during 6-month after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants achieving 3-month continuous abstinence End of Study</measure>
    <time_frame>3-month</time_frame>
    <description>continuous abstinence measured from M9 to M12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>NFL-101 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NFL-101 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will consist of two syringes containing 1 mL of dilution solution, two injections at day 1, two injections at day 8, optional injections later on</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NFL-101 dose 1</intervention_name>
    <description>Subcutaneous injections</description>
    <arm_group_label>NFL-101 Dose 1</arm_group_label>
    <other_name>Tobacco leaf extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NFL-101 dose 2</intervention_name>
    <description>Subcutaneous injections</description>
    <arm_group_label>NFL-101 Dose 2</arm_group_label>
    <other_name>Tobacco leaf extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injections</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>WFI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject ≥ 18 and ≤ 70-year-old;&#xD;
&#xD;
          -  With ECOG/WHO performance status 0-1 (Appendix 1);&#xD;
&#xD;
          -  Subject currently smoking at least 11 cigarettes per day and with a dependency level ≥&#xD;
             3 according to Fagerström Test for Nicotine Dependence scoring (see Appendix 2) [1];&#xD;
&#xD;
          -  Subject willing to quit smoking;&#xD;
&#xD;
          -  Good general health (i.e. no uncontrolled medical condition, or no medical condition&#xD;
             that could interfere with the conduct and the outcomes of the study, according to the&#xD;
             investigator);&#xD;
&#xD;
          -  Good mental health (i.e. no alcohol or drug abuse in the past year, no psychiatric&#xD;
             history- adequately treated depression is accepted);&#xD;
&#xD;
          -  For women of childbearing potential: commitment to consistently and correctly use of a&#xD;
             highly effective contraceptive measure: combined (estrogen and progestogen containing)&#xD;
             hormonal contraception associated with inhibition of ovulation (oral, intravaginal,&#xD;
             transdermal), progestogen-only hormonal contraception associated with inhibition of&#xD;
             ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine&#xD;
             hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner or&#xD;
             sexual abstinence for the duration of the trial; (Females of non-childbearing&#xD;
             potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhoea&#xD;
             duration at least 12 months)) ;&#xD;
&#xD;
          -  Negative pregnancy test at screening visit;&#xD;
&#xD;
          -  Laboratory parameters within the normal range of the laboratory (hematological, blood&#xD;
             chemistry tests). Individual values out of the normal range can be accepted if judged&#xD;
             clinically non relevant by the Investigator;&#xD;
&#xD;
          -  Normal ECG recording on a 12-lead ECG at the screening visit:&#xD;
&#xD;
               -  120 &lt; PR &lt; 210 ms,&#xD;
&#xD;
               -  QRS &lt; 120 ms,&#xD;
&#xD;
               -  QTcf ≤ 430 ms for male and &lt; 450 ms for female,&#xD;
&#xD;
               -  No sign of any trouble of sinusal automatism,&#xD;
&#xD;
               -  Or considered NCs by investigators;&#xD;
&#xD;
          -  Negative prick test at screening visit for the whole study product (extract of Tobacco&#xD;
             leaf and NaCL), and positive for histamine;&#xD;
&#xD;
          -  French speaking subject;&#xD;
&#xD;
          -  Covered by Health Insurance System and / or in compliance with the recommendations of&#xD;
             National Law in force relating to biomedical research.&#xD;
&#xD;
          -  Subject having signed the informed consent agreement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and breastfeeding;&#xD;
&#xD;
          -  Concomitant participation to another clinical trial;&#xD;
&#xD;
          -  Concomitant active infectious diseases;&#xD;
&#xD;
          -  Concomitant use of treatment known to interfere with immune response (not including&#xD;
             desensitization therapies);&#xD;
&#xD;
          -  Uncontrolled diabetes;&#xD;
&#xD;
          -  Prior exposure to a nicotine vaccine or to any other vaccine within 30 days before&#xD;
             study product administration;&#xD;
&#xD;
          -  Concomitant use (and within previous 60 days) of any smoking cessation therapy&#xD;
             (including electronic cigarettes and alternative methods such as hypnosis or&#xD;
             acupuncture);&#xD;
&#xD;
          -  Legal incapacity or physical, psychological or mental status interfering with the&#xD;
             subject's ability to sign the informed consent or to terminate the study.&#xD;
&#xD;
          -  Subject who would receive more than 4500 euros as indemnities for his participation in&#xD;
             biomedical research within the 12 last months, including the indemnities for the&#xD;
             present study Subject who, in the judgment of the Investigator, is likely to be&#xD;
             non-compliant or uncooperative during the study, or unable to cooperate because of a&#xD;
             language problem, poor mental development&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Donazzolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimed Eurofins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Lafont, MS</last_name>
    <phone>+33603063266</phone>
    <email>bruno@sfthera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>College of Health and Medicine, University of Tasmania</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stuart G Ferguson, PhD</last_name>
      <phone>+61 3 6226 4295</phone>
      <email>stuart.ferguson@utas.edu.au</email>
    </contact>
    <investigator>
      <last_name>Stuart G Ferguson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Félix Collet, MSc</last_name>
      <phone>+33(0) 4 38 37 27 48</phone>
      <email>felixcollet@eurofins.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre -Olivier Girodet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Poitiers (CIC 1402)</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire LAFAY-CHEBASSIER, PharmD</last_name>
      <phone>+33 5 49 44 38 36</phone>
      <email>claire.lafay@univ-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice Laine, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NFL Biosciences SAS</investigator_affiliation>
    <investigator_full_name>Yves Donazzolo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

